Dechra Pharmaceuticals (LON:DPH)‘s stock had its “buy” rating reiterated by research analysts at Panmure Gordon in a report released on Thursday, AnalystRatingsNetwork reports. They currently have a GBX 850 ($13.85) price objective on the stock. Panmure Gordon’s price target would indicate a potential upside of 26.30% from the stock’s previous close. DPH has been the […]
Panmure Gordon Reiterates Buy Rating for Dechra Pharmaceuticals (DPH) is a post from: Zolmax
The post Panmure Gordon Reiterates Buy Rating for Dechra Pharmaceuticals (DPH) appeared first on Zolmax.